Tumor-intrinsic immune response and MAPK inhibition
tumor
TUMOR
To understand the potential interaction of BRAF/MAPK pathway inhibition and the tumor immune response, all patients underwent paired pretreatment and day 15 on-treatment biopsies of the same tumor lesion. Fresh tumor biopsies were analyzed by scRNAseq with evaluable data obtained from both paired biopsies in 23 patients. A total of 419,551 single cells passed quality control (QC) across all specimens and stromal, immune and tumor epithelial cell populations (Fig. 